- Home
- SGLY vs INDP Comparison
SGLY vs INDP Comparison
Compare SGLY & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGLY
- INDP
- Stock Information
- Founded
- SGLY 2001
- INDP 2000
- Country
- SGLY United States
- INDP United States
- Employees
- SGLY N/A
- INDP N/A
- Industry
- SGLY
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- SGLY
- INDP Health Care
- Exchange
- SGLY Nasdaq
- INDP Nasdaq
- Market Cap
- SGLY 15.9M
- INDP 15.4M
- IPO Year
- SGLY 2008
- INDP N/A
- Fundamental
- Price
- SGLY $1.62
- INDP $1.16
- Analyst Decision
- SGLY
- INDP Strong Buy
- Analyst Count
- SGLY 0
- INDP 1
- Target Price
- SGLY N/A
- INDP $12.00
- AVG Volume (30 Days)
- SGLY 204.2K
- INDP 21.1K
- Earning Date
- SGLY 11-11-2024
- INDP 11-04-2024
- Dividend Yield
- SGLY N/A
- INDP N/A
- EPS Growth
- SGLY N/A
- INDP N/A
- EPS
- SGLY N/A
- INDP N/A
- Revenue
- SGLY $3,370,424.00
- INDP N/A
- Revenue This Year
- SGLY N/A
- INDP N/A
- Revenue Next Year
- SGLY N/A
- INDP N/A
- P/E Ratio
- SGLY N/A
- INDP N/A
- Revenue Growth
- SGLY N/A
- INDP N/A
- 52 Week Low
- SGLY $1.27
- INDP $1.03
- 52 Week High
- SGLY $8.00
- INDP $3.25
- Technical
- Relative Strength Index (RSI)
- SGLY 40.85
- INDP 36.05
- Support Level
- SGLY $1.27
- INDP $1.11
- Resistance Level
- SGLY $1.79
- INDP $1.27
- Average True Range (ATR)
- SGLY 0.28
- INDP 0.13
- MACD
- SGLY 0.07
- INDP -0.00
- Stochastic Oscillator
- SGLY 29.67
- INDP 22.03
About SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.